SULSA INDUSTRY SPONSORS
Meet our SULSA Industry Sponsors who work closely with SULSA to ensure better collaboration across universities and industry to meet the challenges in innovation and skills demand.
LifeArc
LifeArc® is a medical research charity making life science life changing, transforming promising life science ideas into medical breakthroughs that change patients’ lives. They are self-funding and specialise in early-stage translation advancing lab-based scientific discoveries to a point at which they can be developed into the next generation of diagnostics, treatments and cures.
LifeArc have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. This includes Keytruda®(cancer), Actemra® (rheumatoid arthritis), Tysabri® (multiple sclerosis) and Entyvio® (Crohn’sdisease) and a test for antimicrobial resistance.
Merck
Merck is the oldest pharmaceutical company in the world, established over 250 years ago, operating in 66 countries. Their passion for science and technology is what drives more than 64,000 employees to find solutions to some of today’s toughest challenges and create more sustainable ways to live.
Merck deliver personalised treatments for serious diseases and their tools, services, and digital platform make research simpler, more exact, and help to deliver breakthroughs more quickly. They provide progressive treatment solutions that help improve access to health thanks to the accuracy of their tests and the reliability of their medicine. As a company, they are at the forefront of digital living. Their science sits inside technologies that change the way we access, store, process, and display information. And their innovative technology drives human progress and opens new possibilities to transform life on Earth as we know it.
RoukenBio
RoukenBio (formerly Antibody Analytics) are inspired by deconstructing the relative contributions of primary immune cells to disease pathology. Their goal is to provide physiologically relevant, in vitro models, that facilitate the mechanistic investigation of biologics and novel therapeutic approaches. With translational immunology platforms, cell line engineering services, biophysical characterisation (SPR), effector function packages and bioassay development capabilities, they can support biopharmaceutical companies seeking to overcome substantial scientific challenges from the very earliest stages of the drug discovery journey.
RoukenBio are experienced in characterising therapeutics that modulate the immune response. With a strong focus on targeted therapeutics, these include monoclonal antibodies, immune cell engagers, antibody drug conjugates, engineered cell therapies, oncolytic viruses, multi-functional biologics and novel platform technologies.
